Kybora

The Foundation Rwanda KYBORA Initiative – Meet Paulin Nkusi

December 4, 2023
News
Paulin Nkusi KYBORA is proud to be working with Foundation Rwanda on a program that empowers second-generation rape survivors of the Rwandan genocide Meet Paulin, a second-generation survivor and entrepreneur…
READ MORE

Navigating the Complex Intellectual Property Landscape as a Biotech CEO

August 24, 2023
News
As a Biotech CEO, steering a company through the dynamic landscape of innovation comes with a unique set of challenges,…
READ MORE

Exploring Funding Avenues for your Biotech Venture

August 22, 2023
News
In the dynamic landscape of biotech, securing the right funding is the heartbeat of progress. For innovative startups in this…
READ MORE

Licensing Strategies for Biotech CEOs

August 18, 2023
News
Biotech research and development serve as the bedrock of groundbreaking advancements, but the journey often demands substantial financial backing. CEOs…
READ MORE

KYBORA is pleased to announce that Wang Zhi has joined its team at EVP and Managing Director of its Asia Pac operations.

June 21, 2023
News
SHANGHAI AND PRINCETON, N.J. JUNE 09, 2023KYBORA Life Sciences, a global advisory firm dedicated to facilitating enduring success for life…
READ MORE

Q1 2023 Global Biopharma Market Trends and News

April 12, 2023
News
In this report (download here) , Q1 2023 Global Biopharma Market Trends and News, we cover the key Biotech/Pharma trends…
READ MORE

KYBORA is happy to announce that Khai Meng Ang has joined its team as Senior Advisor for China.

February 6, 2023
News
KYBORA's mission is to help life science companies achieve enduring success. Khai's addition to our team allows us to provide…
READ MORE

KYBORA is pleased to announce that its client Megalabs has acquired acquired Fr!ska.

February 3, 2023
Mergers and Acquisitions, News
KYBORA is pleased to announce that its client Megalabs has acquired acquired Fr!ska.
READ MORE

KYBORA is pleased to announce the licensing of Daewoong’s development stage IPF therapy (Bersiporocin) to CS Pharmaceuticals for the Greater China region.

February 3, 2023
Global Licensing, News
KYBORA is pleased to announce the licensing of Daewoong's development stage IPF therapy (Bersiporocin) to CS Pharmaceuticals for the Greater China…
READ MORE

KYBORA is pleased to announce that its trademarks have been approved and registered by the Chinese government.

June 24, 2022
News
KYBORA and its Chinese translation (pronounced KAI-BO-RUI) have both been granted official trademark status by the People's Republic of China.
READ MORE

KYBORA is pleased to announce the partnering of ORLADEYO® (berotralstat) in Latin America.

June 14, 2022
Global Licensing, News
KYBORA is please to announce that its client Pint Pharma has completed an agreement to commercialize Orladeyo in Latin America
READ MORE

KYBORA is pleased to announce the licensing of Accure Therapeutics ACT-01 to Oculis.

March 2, 2022
Global Licensing
KYBORA is pleased to announce the global licensing of ACT-01 from Accure Therapeutics to Oculis. This transaction further demonstrates KYBORA's…
READ MORE
Howard Lei Joined KYBORA

KYBORA Welcomes Howard Lei To its Team

December 22, 2021
News
Princeton, NJ – October 12th, 2021 KYBORA is pleased to announce that Howard Lei (MBA, MS-IT, PMP) has joined its…
READ MORE

TYPE & ENTER: